ARPA-H committed $90.7 million over four years under its Making Obstetrics Care Smart (MOCS) program to fund diagnostic tests and fetal monitoring technologies aimed at reducing risks during childbirth. The effort begins June 16 and includes rapid point-of-care approaches using genomic and proteomic methods to identify fetal hypoxia risk. Among funded projects, teams at UC San Diego will develop a POC blood test assessing fetal and maternal proteins, nucleic acids, and extracellular vesicles, with Sera Prognostics and Allegro MicroSystems as commercial collaborators. Wyss Institute at Harvard, led by Jim Collins, will pursue a microfluidic POC device to evaluate fetal extracellular vesicle mRNA content to predict oxygenation risk. The program also supports autonomous wearable ultrasound monitoring to assess placental health during labor without a specialist operator, pairing fetal heart rate and contraction data with AI-based modeling to estimate oxygen levels in real time.